Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review

Khan, Nazish; Cox, Anthony R.; Cotton, James

doi:10.1016/j.thromres.2016.05.019

Cited by 15 publications

(11 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although prasugrel and ticagrelor are both Adenosine diphosphate (ADP)-receptor antagonists, there are a number of differences between them, including their pharmacodynamics, drug interactions and side-effect profile 11. Switching between the two agents produces demonstrable changes in platelet function 11 12.…”

Section: Introductionmentioning

confidence: 99%

Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention

Olier

Sirker

Hildick‐Smith

et al. 2018

Heart

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention

Olier

Sirker

Hildick‐Smith

et al. 2018

Heart

View full text Add to dashboard Cite

show abstract

“…In stable patients, maximum platelet inhibition with ticagrelor is achieved 1 hour after administration, while clopidogrel takes 6 -12 hours for its maximal efficiency. Also, platelets regain their normal reactivity upon 3 days after cessation of ticagrelor therapy, which occurs after 5-7 days after clopidogrel cessation 22 . With faster onset of action and consistent reversible platelet inhibition, ticagrelor proved its superiority over clopidogrel in patients with ACS by significantly reducing ischemic risk by 16%, without increasing the risk of hemorrhage 23 .…”

Section: Antiplatelet Agentsmentioning

confidence: 97%

Dual antiplatelet therapy in coronary artery disease

Rakočević¹,

Tomasević²,

Aleksandrić³

et al. 2018

Srce i krvni sudovi

View full text Add to dashboard Cite

Coronary artery disease encompasses a spectrum of clinical presentations caused by underlying coronary atherosclerosis. Acute manifestations of atherosclerotic disease occur when rupture/erosion of atherosclerotic plaque becomes substrate for platelet activation and aggregation, which have a central role in the formation and propagation of intracoronary thrombi. Therefore, antiplatelet therapy represents a standard of care in the primary and secondary prevention of CAD. Dual antiplatelet therapy (DAPT) typically refers to aspirin along with P2Y12 receptor inhibitor (clopidogrel, prasugrel or ticagrelor). Choice and duration of DAPT requires an individual approach and assessment of each patient, emphasizing the tailored antiplatelet treatment. This is largely driven by patient's clinical presentation (stable coronary artery disease or acute coronary syndrome), existing risk factors (ischemic vs. hemorrhagic risk), and following treatment plan (medical treatment, percutaneous coronary intervention, or coronary artery bypass graft). In this review, we present the evidence supporting DAPT administration and therapy duration in different subpopulations of patients with CAD. Also, we will review these data in the context of current 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease, emphasizing the novelties from the present guidelines.

show abstract

“…The onset of action of ticagrelor and prasugrel is, respectively, 30 minutes and 60 minutes. 7 Prasugrel was shown to be superior to clopidogrel in patients with ACS undergoing PCI, with reductions in the rates of death from cardiovascular causes, infarction, stroke, and a 52% relative reduction for stent thrombosis. However, rates of major bleeding and life-threating bleeding were greater in patients receiving prasugrel compared with clopidrogrel.…”

Section: P2y 12 Inhibitorsmentioning

confidence: 99%

Reperfusion Strategies in Acute Myocardial Infarction: State of the Art

Rangel¹

2021

International Journal of Cardiovascular Sciences

View full text Add to dashboard Cite

ST elevation myocardial infarction (STEMI) is a highly prevalent condition worldwide. Reperfusion therapy is strongly associated with the prognosis of STEMI and must be performed with a high standard of quality and without delay. A systematic review of different reperfusion strategies for STEMI was conducted, including randomized controlled trials that included major cardiovascular events (MACE), and systematic reviews in the last 5 years through the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) methodology. The research was done in the PubMed and Cochrane Central Register of Controlled Trials databases, in addition to a few manual searches. After the exclusion criteria were applied, 90 articles were selected for this review. Despite the reestablishment of IRA patency in PCI for STEMI, microvascular lesions occur in a significant proportion of these patients, which can compromise ventricular function and clinical course. Several therapeutic strategies -intracoronary administration of nicorandil, nitrates, melatonin, antioxidant drugs (quercetin, glutathione), antiinflammatory substances (tocilizumab [an inhibitor of interleukin 6], inclacumab, P-selectin inhibitor), immunosuppressants (cyclosporine), erythropoietin and ischemic pre-and post-conditioning and stem cell therapy -have been tested to reduce reperfusion injury, ventricular remodeling and serious cardiovascular events, with heterogeneous results: These therapies need confirmation in larger studies to be implemented in clinical practice PrevalenceThe worldwide prevalence of ischemic heart disease is approximately 111 million cases, with 7.3 million cases of fatal acute myocardial infarction (AMI) in 2015. The inadequate treatment of patients with AMI is associated with significant increases in morbidity and mortality. 1 ObjectivesThe objective of this systematic review is to evaluate the evidence of different reperfusion therapies in STsegment elevation AMI (STEMI), selecting mainly randomized controlled trials and systematic reviews that address major cardiovascular clinical outcomes. MethodsThe review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). We searched the PubMed database for the terms "acute myocardial infarction" and "reperfusion therapy", which yielded 9,885 results. After applying the following search filters -type of abstract: "text and full text"; type of article: "metaanalysis, review, systematic review and randomized clinical trial", and date of publication: "last 5 years", and language: "English" -127 articles were obtained. In addition, research was conducted at the Cochrane Central Register of Controlled Trials using the terms "acute myocardial infarction" and "reperfusion therapy", in English, between 2018 and 2020, which revealed 64 clinical trials, already excluding duplicates. Of the 191

show abstract

Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review

Cited by 15 publications

References 54 publications

Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention

Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention

Dual antiplatelet therapy in coronary artery disease

Reperfusion Strategies in Acute Myocardial Infarction: State of the Art

Contact Info

Product

Resources

About